Regeneron's Eylea granted priority review in diabetic retinopathy
This article was originally published in Scrip
Executive Summary
If all goes according to plan, Regeneron Pharmaceuticals could have a verdict from the FDA by 30 March 2015 for Eylea (aflibercept) as a treatment for diabetic retinopathy in patients with diabetic macular edema (DME).